Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the effects of intravenous Lidocaine versus intravenous Ketamine in patients undergoing open colorectal surgery for cancer. This randomized controlled trial aims to compare how these two drugs influence inflammation by measuring Interleukin-6 IL-6 levels before anesthesia and 24 hours after surgery. The study also assesses pain, nausea, bowel function, hospital stay length, and postoperative complications to better understand treatment impacts. Participants are randomly assigned to one of two groups. The Lidocaine group receives a loading dose of 1.5 mgkg followed by a continuous infusion of 1.5 mgkg per hour for 24 hours. The Ketamine group receives a loading dose of 0.15 mgkg followed by a continuous infusion of 0.15 mgkg per hour over the same period. Both treatments are administered intravenously during and after surgery. During the study, patients will have blood samples taken to measure IL-6 levels before anesthesia and 24 hours after surgery. Pain will be evaluated using a numerical scale at 2, 12, and 24 hours postoperatively. Nausea, vomiting, bowel function, length of hospital stay, and complications will be monitored for up to 15 days after surgery. The entire participation includes treatment and follow-up assessments to observe recovery and outcomes.
Actively Recruiting
Researchers are evaluating whether taking 800 mg of oral ginger two hours before laparoscopic gallbladder removal surgery laparoscopic cholecystectomy can reduce the occurrence and severity of nausea and vomiting after surgery. This study is a double-blind, randomized controlled trial sponsored by the University Tunis El Manar and focuses on patients aged 18 and older undergoing this surgery. Participants are randomly assigned to one of two groups one group receives 800 mg of ginger orally two hours before surgery, and the other group receives a placebo capsule that looks identical to the ginger capsule, also two hours before surgery. The study monitors outcomes within the first 24 hours after surgery. During the trial, researchers will assess the incidence of nausea and vomiting within 2 hours after surgery as the primary outcome. Secondary outcomes include recurrence of nausea and vomiting from 2 to 24 hours after surgery, total vomiting episodes, use of rescue anti-nausea medications, and any ginger-related side effects in the 24-hour post-surgery period. Participants will be evaluated through follow-up during this time to monitor these effects and ensure safety.